# A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica

> **NCT01364389** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 16 (actual)

## Conditions studied

- Polymyalgia Rheumatica
- Inflammatory Diseases

## Interventions

- **DRUG:** AIN457
- **DRUG:** ACZ885
- **DRUG:** Prednisone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01364389
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-02-14
- **Primary completion:** 2013-01-29
- **Final completion:** 2013-01-29
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Data did not show that the two biologic treatments impacted PMR disease activity to the same degree as steroid treatment within a 2-week treatment period.
- **Last updated:** 2021-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01364389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01364389, "A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT01364389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*